media – Page 568 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Blockchain medical device set to improve the delivery for babies born by C-section

NnBu Holdings has developed a blockchain medical device to help deliver healthy outcomes for babies born by C-section.
- Source: Open Access Government
- 672
- March 19, 2018
blockchain digital health Researches
Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the FDA has granted Rare Pediatric Disease Designation for the ABO-202 program (AAV-CLN1), an AAV-based gene therapy for the treatment of CLN1 disease (infantile and late infantile onset Batten disease).
- Source: Tmcnet
- 439
- March 19, 2018
CLN1 disease lysosomal storage New Approvals
Autism’s social deficits are reversed by an anti-cancer drug

Using an epigenetic mechanism, romidepsin restored gene expression and alleviated social deficits in animal models of autism
- Source: Sciencedaily
- 510
- March 19, 2018
autism Researches romidepsin
Artificial Intelligence powers new lung health app

Aseptika in St Ives and Zenzium in Cheshire have been awarded an unspecified grant from the UK’s innovation agency to leverage AI and develop a new home-based early warning system for people with severe respiratory disease.
- Source: Business Weekly
- 631
- March 19, 2018
AI COPD Researches respiratory
Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported interim clinical data of BPX-501 in pediatric patients with acute myeloid leukemia (AML) and primary immunodeficiencies (PIDs). BPX-501 is an adjunct T cell therapy incorporating CaspaCIDe® administered after haploidentical hematopoietic stem cell transplant (haplo-HSCT) for the treatment of hematologic cancers and inherited blood diseases.
- Source: ir.bellicum
- 560
- March 19, 2018
AML BPX-501 Clinical Trials PIDs T cell therapy
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer

Erdafitinib, an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, shows promise as the first targeted agent for patients with metastatic urothelial cancer, one of the most common cancers
- Source: janssen
- 629
- March 19, 2018
erdafitinib FDA Janssen Johnson & Johnson
mHealth Tools, AI Combine to Avert Serious Diabetic Health Issues

mHealth tools embedded with AI technology are helping doctors and those living with diabetes detect hyperglycemia and hypoglycemia up to an hour ahead of time, averting serious and potentially fatal health issues.
- Source: drugdu
- 1,254
- March 19, 2018
AI Company Insight digital health mHealth
Preview — Global Pharmaceutical and Medical Device Exhibitions in the Second Quarter of 2018

Have you prepared for all the exhibitions you want to attend in the second quarter of 2018? Ddu, the leading global pharmaceutical & medical device B2B online platform, plans to attend a number of major international pharmaceutical and medical device exhibitions in the second quarter of this year. Here is a summary of each event:
- Source: Ddu
- 150,863
- March 16, 2018
Exhibitions & Activities medical device pharmaceutical
GlaxoSmithKline chief Emma Walmsley nets $6.8M in pay in her first year at the helm

Investors who pressed GlaxoSmithKline to slash new CEO Emma Walmsley’s pay package before she took the helm probably won’t much like her overall compensation figure for 2017.
- Source: fiercepharma
- 560
- March 16, 2018
Company Insight GSK
Boehringer, Vanderbilt U to develop cancer MCL1 inhibitors in third team-up

Cancer cells are different from normal cells in that they can avoid a naturally programmed cell death process known as apoptosis and grow almost indefinitely. In their third collaboration, Boehringer Ingelheim and Vanderbilt University have their eyes on a target that helps cancer cells evade death.
- Source: fiercebiotech
- 458
- March 16, 2018
apoptosis Company Insight MCL1

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.